Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, Rae Sung | - |
dc.contributor.author | Suh, Min Sung | - |
dc.contributor.author | Kim, Sunil | - |
dc.contributor.author | Shim, Gayong | - |
dc.contributor.author | Lee, Sangbin | - |
dc.contributor.author | Han, Sung Sik | - |
dc.contributor.author | Lee, Kyung Eun | - |
dc.contributor.author | Jeon, Hyesung | - |
dc.contributor.author | Choi, Han-Gon | - |
dc.contributor.author | Choi, Yongseok | - |
dc.contributor.author | Kim, Chan-Wha | - |
dc.contributor.author | Oh, Yu-Kyoung | - |
dc.date.accessioned | 2021-06-23T10:04:16Z | - |
dc.date.available | 2021-06-23T10:04:16Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2011-12 | - |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/36367 | - |
dc.description.abstract | Combined treatment of anticancer drugs and small interfering RNAs (siRNAs) have emerged as a new modality of anticancer therapy. Here, we describe a co-delivery system of anticancer drugs and siRNA in which anticancer drug-derived lipids form cationic nanoparticles for siRNA complexation. The anticancer drug mitoxantrone (MTO) was conjugated to palmitoleic acid, generating two types of palmitoleyl MTO (Pal-MTO) lipids: monopalmitoleyl MTO (mono-Pal-MTO) and dipalmitoleyl MTO (di-Pal-MTO). Among various lipid compositions of MTO, nanoparticles containing mono-Pal-MTO and di-Pal-MTO at a molar ratio of 1:1 (md11-Pal-MTO nanoparticles) showed the most efficient cellular delivery of siRNA, higher than that of Lipofectamine 2000. Delivery of red fluorescence protein-specific siRNA into B16F10-RFP cells using md11-Pal-MTO nanoparticles reduced the expression of RIP at both mRNA and protein levels, demonstrating silencing of the siRNA target gene. Moreover, delivery of Mcl-1-specific anticancer siRNA (siMcl-1) using md11-Pal-MTO enhanced antitumor activity in vitro, reducing tumor cell viability by 81% compared to a reduction of 68% following Lipofectamine 2000-mediated transfection of siMcl-1. Intratumoral administration of siMcl-1 using md11-Pal-MTO nanoparticles significantly inhibited tumor growth, reducing tumor size by 83% compared to untreated controls. Our results suggest the potential of md11-Pal-MTO multifunctional nanoparticles for co-delivery of anticancer siRNAs for effective combination therapy. (C) 2011 Elsevier Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.title | Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Han-Gon | - |
dc.identifier.doi | 10.1016/j.biomaterials.2011.09.017 | - |
dc.identifier.scopusid | 2-s2.0-80054060205 | - |
dc.identifier.wosid | 000296821800025 | - |
dc.identifier.bibliographicCitation | BIOMATERIALS, v.32, no.36, pp.9785 - 9795 | - |
dc.relation.isPartOf | BIOMATERIALS | - |
dc.citation.title | BIOMATERIALS | - |
dc.citation.volume | 32 | - |
dc.citation.number | 36 | - |
dc.citation.startPage | 9785 | - |
dc.citation.endPage | 9795 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Engineering | - |
dc.relation.journalResearchArea | Materials Science | - |
dc.relation.journalWebOfScienceCategory | Engineering, Biomedical | - |
dc.relation.journalWebOfScienceCategory | Materials Science, Biomaterials | - |
dc.subject.keywordPlus | MESOPOROUS SILICA NANOPARTICLES | - |
dc.subject.keywordPlus | RNA INTERFERENCE | - |
dc.subject.keywordPlus | DOWN-REGULATION | - |
dc.subject.keywordPlus | CARCINOMA CELLS | - |
dc.subject.keywordPlus | INHIBITS GROWTH | - |
dc.subject.keywordPlus | GENE DELIVERY | - |
dc.subject.keywordPlus | CANCER-CELLS | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | MCL-1 | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordAuthor | siRNA | - |
dc.subject.keywordAuthor | Mitoxantrone | - |
dc.subject.keywordAuthor | Multifunctional nanoparticles | - |
dc.subject.keywordAuthor | Co-delivery | - |
dc.subject.keywordAuthor | Anticancer chemo-gene therapy | - |
dc.identifier.url | https://www.science.org/doi/10.1126/science.1211936 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.